In 2010, the cost to bring a novel drug to market was estimated to cost $1.8 billion.* Naturally, this cost, along with the inherent risk of most drug candidates failing, has made pharmaceutical companies increasingly risk averse as they select which new drug candidates to pursue and which ones to indefinitely defer. Since stroke, cancer, neuro-degenerative, and infectious diseases are among the leading causes of death in the USA every year**, not-for-profit organizations help to fill the void.
*Nature Reviews, 2010
**Centers for Disease Control and Prevention, 2010
The University of Notre Dame has a cohort of investigators who have been making groundbreaking research discoveries for decades. Amongst these research discoveries are thousands of novel molecular compounds that could be the cures of the world’s most serious diseases. In years past, the most promising novel molecular compounds would have been readily licensed to pharmaceutical companies for further development and then brought to market to relieve the suffering of patients. However, rising costs and risks have delayed the involvement of pharmaceutical companies, leaving a void in the development process.
WFCDDD is brand new, but it will build on the University of Notre Dame’s current drug development and licensing successes. Pharmaceutical companies are already licensing intellectual property created and developed at Notre Dame. So, the capabilities are proven. That’s why The William K. Warren Foundation partnered with Notre Dame to generate and accelerate even more chances for novel drug development success. Immediate drug development candidates for Alzheimer’s disease, stroke, tuberculosis, and several rare diseases are already being accelerated and pursued as a result of the Foundation’s support.